Oncolytics Biotech (ONCY) Competitors $1.05 -0.09 (-7.89%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.48%) As of 07/25/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. KMDA, TERN, RGNX, SVRA, TECX, FULC, SLDB, PASG, PRTC, and SNDLShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Savara (SVRA), Tectonic Therapeutic (TECX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Passage Bio (PASG), PureTech Health (PRTC), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Kamada Terns Pharmaceuticals REGENXBIO Savara Tectonic Therapeutic Fulcrum Therapeutics Solid Biosciences Passage Bio PureTech Health SNDL Kamada (NASDAQ:KMDA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Do insiders and institutionals hold more shares of KMDA or ONCY? 20.4% of Kamada shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend KMDA or ONCY? Kamada currently has a consensus target price of $13.00, indicating a potential upside of 68.39%. Oncolytics Biotech has a consensus target price of $4.33, indicating a potential upside of 312.70%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, KMDA or ONCY? Kamada has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Does the media refer more to KMDA or ONCY? In the previous week, Oncolytics Biotech had 5 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Oncolytics Biotech and 2 mentions for Kamada. Kamada's average media sentiment score of 1.78 beat Oncolytics Biotech's score of 0.11 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings & valuation, KMDA or ONCY? Kamada has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.76$14.46M$0.2926.62Oncolytics BiotechN/AN/A-$23.14M-$0.29-3.62 Is KMDA or ONCY more profitable? Kamada has a net margin of 9.60% compared to Oncolytics Biotech's net margin of 0.00%. Kamada's return on equity of 6.31% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.60% 6.31% 4.43% Oncolytics Biotech N/A -313.77%-130.19% SummaryKamada beats Oncolytics Biotech on 10 of the 15 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.48M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-3.6221.1828.1020.05Price / SalesN/A288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book21.008.378.665.87Net Income-$23.14M-$55.19M$3.25B$258.55M7 Day Performance-17.32%5.88%4.23%3.74%1 Month Performance45.83%17.33%10.52%11.75%1 Year Performance0.96%4.42%34.41%18.03% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.8147 of 5 stars$1.05-7.9%$4.33+312.7%+1.0%$107.48MN/A-3.6230News CoverageUpcoming EarningsKMDAKamada4.3245 of 5 stars$7.78+0.4%$13.00+67.1%+30.0%$447.39M$167.24M26.83360News CoveragePositive NewsTERNTerns Pharmaceuticals3.9798 of 5 stars$5.11+4.3%$15.63+205.8%-31.2%$446.31MN/A-4.6940RGNXREGENXBIO4.2825 of 5 stars$8.70+0.2%$31.63+263.5%-37.7%$436.39M$83.33M-2.80370News CoveragePositive NewsSVRASavara1.8749 of 5 stars$2.51+5.0%$5.60+123.1%-43.7%$433.83MN/A-5.2320Positive NewsTECXTectonic Therapeutic2.7025 of 5 stars$23.12+2.1%$83.60+261.6%+31.3%$431.72MN/A-3.16120Analyst DowngradeFULCFulcrum Therapeutics0.4921 of 5 stars$7.90+0.9%$6.29-20.4%-9.6%$426.44M$80M-112.84100Upcoming EarningsSLDBSolid Biosciences3.0988 of 5 stars$5.47+4.0%$15.10+176.1%-22.7%$423.98M$8.09M-1.83100PASGPassage Bio3.3868 of 5 stars$6.79-15.3%$150.00+2,109.1%-57.7%$423.76MN/A-6.66130News CoveragePositive NewsInsider TradeGap UpHigh Trading VolumePRTCPureTech Health2.785 of 5 stars$17.56-1.4%$45.00+156.3%-14.4%$421.65M$4.32M0.00100Positive NewsUpcoming EarningsSNDLSNDL1.7229 of 5 stars$1.58+13.7%$3.63+129.4%-28.9%$415.19M$671.81M-5.452,516News CoverageUpcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Kamada Competitors Terns Pharmaceuticals Competitors REGENXBIO Competitors Savara Competitors Tectonic Therapeutic Competitors Fulcrum Therapeutics Competitors Solid Biosciences Competitors Passage Bio Competitors PureTech Health Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCY Stock Alerts